- Home
- DOX vs ROIV Comparison
DOX vs ROIV Comparison
Compare DOX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOX | ROIV |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 20.7B |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOX | ROIV |
|---|---|---|
| Price | $66.37 | $28.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $92.33 | $27.56 |
| AVG Volume (30 Days) | 1.0M | ★ 4.5M |
| Earning Date | 05-06-2026 | 02-06-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $3.76 | $594.84 |
| P/E Ratio | $13.65 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $63.33 | $8.73 |
| 52 Week High | $94.61 | $30.33 |
Technical Indicators
Market Signals| Indicator | DOX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.46 | 56.22 |
| Support Level | $66.13 | $26.94 |
| Resistance Level | $70.61 | $30.33 |
| Average True Range (ATR) | 1.66 | 0.95 |
| MACD | 0.39 | -0.12 |
| Stochastic Oscillator | 63.30 | 79.20 |
Price Performance
Historical ComparisonAbout DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, entertainment, and media service providers. The Company operates in a single segment and designs, develops, markets, supports, implements, and operates open and modular cloud offerings. Its portfolio includes solutions across digital business systems and legacy business and operational support systems, supporting multiple lines of business such as wireless, broadband, cable, fiber, satellite, and digital services. The Company leverages artificial intelligence to support digital transformation, cloud adoption, and intelligent network automation. Geographically, it derives a majority of its revenue from North America and also operates in Europe and the rest of the world.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.